The Value of Self-Care in Public Health: Insights and Implications for Europe

By Rene Pretorius

July 2, 2025

Summary
Self-care in public health is a critical pillar of public health in Europe. It enables individuals to manage minor ailments independently while easing pressure on healthcare systems. By using non-prescription medicines, devices, and supplements, self-care cuts costs, saves time, and boosts productivity. Evidence shows that the value of self-care in public health amounts to annual savings of €36 billion and averted productivity losses of €10 billion.

Key Insights
Reported study findings highlight self-care’s economic and social value. Europe avoids €36 billion yearly by managing 1.2 billion minor health issues through self-care. This includes €26 billion in medical expenses and €10 billion in productivity losses. Self-care also reduces GP workloads. It equals needing 120,000 extra doctors or 2.4 more hours daily for current practitioners. Consumer behavior is shifting toward prevention. 84% take preventive measures, and 67% spend over €21 monthly on health aids.

Background Context
Research shows self-care’s role in tackling healthcare challenges. The AESGP notes it empowers individuals with low-cost solutions for minor ailments. EU eHealth initiatives improve access to electronic records. The eHealth score reached 83% in 2024, supporting self-care goals.

Implications
For health economics, self-care offers a scalable, cost-effective solution. It helps strained systems as populations age and chronic diseases rise. Stronger policies could optimize resources, letting providers focus on complex cases. Public health efforts can align with preventive trends, reducing reliance on costly interventions. Barriers like uneven regulations and education gaps may limit uptake. Future steps include digital health tools to enhance self-care, matching EU digital goals.

Reference url

Recent Posts

Strengthening Supply Chains: The EU Critical Medicines Act

By João L. Carapinha

May 12, 2026

The European Medicines Agency (EMA) has welcomed the provisional political agreement on the EU Critical Medicines Act, an initiative designed to enhance the availability, production, and supply of critical medicines throughout the European Union. This agreement represents a key a...
Johnson & Johnson Advances Neuropsychiatry Treatment Innovations at APA and ASCP Conferences
Neuropsychiatry treatment innovations continue to reshape care for complex conditions. At the recent APA and ASCP meetings, Johnson & Johnson presented new portfolio and pipeline data focused on major depressive disorder, treatment-resistant depression, and schizophrenia — offering p...
Marstacimab Cost-Effectiveness Analysis in Hemophilia Treatment: A Portuguese Assessment
The public assessment report for Hympavzi (marstacimab) in Portugal concludes that the product offers no added therapeutic value relative to recombinant factor VIII concentrates and emicizumab in patients aged 12 years and older weighing at least 35 kg with severe hemophilia A without factor VIII...